Development of charybdotoxin Q18F variant as a selective peptide blocker of neuronal BK(α + β4) channel for the treatment of epileptic seizures.

Animals Humans Rats Charybdotoxin / chemistry Epilepsy / drug therapy Large-Conductance Calcium-Activated Potassium Channels / metabolism Neurons / metabolism Peptides / metabolism Seizures / drug therapy
BK(α + β4) channel anti-epilepsy charybdotoxin Q18F nuclear magnetic resonance

Journal

Protein science : a publication of the Protein Society
ISSN: 1469-896X
Titre abrégé: Protein Sci
Pays: United States
ID NLM: 9211750

Informations de publication

Date de publication:
12 2022
Historique:
revised: 04 11 2022
received: 23 04 2022
accepted: 06 11 2022
pubmed: 13 11 2022
medline: 2 12 2022
entrez: 12 11 2022
Statut: ppublish

Résumé

Epilepsy is the results from the imbalance between inhibition and excitation in neural circuits, which is mainly treated by some chemical drugs with side effects. Gain-of-function of BK channels or knockout of its β4 subunit associates with spontaneous epilepsy. Currently, few reports were published about the efficacy of BK(α + β4) channel modulators in epilepsy prevention. Charybdotoxin is a non-specific inhibitor of BK and other K

Identifiants

DOI: 10.1002/pro.4506 PMID: 36369672 PMC: PMC9703589
pubmed: 36369672
doi: 10.1002/pro.4506
pmc: PMC9703589
doi:

Substances chimiques

Charybdotoxin 115422-61-2
Large-Conductance Calcium-Activated Potassium Channels 0
Peptides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e4506

Informations de copyright

© 2022 The Protein Society.

Références

J Neurosci. 2000 May 15;20(10):3563-70
pubmed: 10804197
Sci Rep. 2016 Jul 11;6:29431
pubmed: 27403813
Front Physiol. 2014 Oct 09;5:389
pubmed: 25346695
J Physiol. 2004 May 15;557(Pt 1):147-57
pubmed: 15034127
Proc Natl Acad Sci U S A. 2012 May 15;109(20):7917-22
pubmed: 22547800
J Biol Chem. 1998 Jun 26;273(26):16289-96
pubmed: 9632689
Expert Opin Ther Targets. 2011 Nov;15(11):1283-95
pubmed: 21923633
Sci Rep. 2018 Mar 15;8(1):4571
pubmed: 29545539
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):4137-42
pubmed: 10097176
Nature. 2017 Jan 5;541(7635):46-51
pubmed: 27974795
Nature. 2010 Jul 15;466(7304):393-7
pubmed: 20574420
Epilepsia. 2009 Apr;50(4):711-20
pubmed: 19054419
Toxins (Basel). 2014 Apr 22;6(4):1419-33
pubmed: 24759175
Protein Sci. 2000 Sep;9(9):1709-18
pubmed: 11045617
Physiol Rev. 2017 Jan;97(1):39-87
pubmed: 27807200
J Physiol. 1999 Nov 15;521 Pt 1:135-46
pubmed: 10562340
Elife. 2019 Dec 09;8:
pubmed: 31815672
News Physiol Sci. 2002 Aug;17:156-61
pubmed: 12136044
Epilepsy Behav. 2009 May;15(1):56-65
pubmed: 19236951
Assay Drug Dev Technol. 2011 Aug;9(4):342-53
pubmed: 21812660
Nat Protoc. 2018 Jun;13(6):1403-1428
pubmed: 29844522
J Gen Physiol. 2006 Apr;127(4):449-65
pubmed: 16567466
Neurobiol Dis. 2008 Jun;30(3):323-330
pubmed: 18387812
Proc Natl Acad Sci U S A. 1988 May;85(10):3329-33
pubmed: 2453055
Protein Sci. 2022 Dec;31(12):e4506
pubmed: 36369672
Nature. 2017 Jan 5;541(7635):52-57
pubmed: 27974801
Eur J Neurosci. 2002 Oct;16(7):1214-22
pubmed: 12405981
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9200-5
pubmed: 8799178
J Biomol NMR. 1995 Nov;6(3):277-93
pubmed: 8520220
Science. 1993 Jul 9;261(5118):221-4
pubmed: 7687074
J Biol Chem. 2000 Mar 3;275(9):6453-61
pubmed: 10692449
Nat Genet. 2005 Jul;37(7):733-8
pubmed: 15937479
Nat Neurosci. 2005 Dec;8(12):1752-9
pubmed: 16261134
J Biomol NMR. 1996 Dec;8(4):477-86
pubmed: 9008363
Mass Spectrom Rev. 2006 Jul-Aug;25(4):663-82
pubmed: 16477643
Toxins (Basel). 2016 Sep 27;8(10):
pubmed: 27690098
Nat Commun. 2015 Jul 31;6:7859
pubmed: 26227798
J Med Chem. 2020 Jan 9;63(1):216-230
pubmed: 31838846
Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):281-94
pubmed: 4110397
Evid Based Complement Alternat Med. 2019 Mar 18;2019:4534167
pubmed: 31011358
Expert Rev Clin Pharmacol. 2017 Sep;10(9):993-1006
pubmed: 28689437
J Physiol. 2003 Oct 15;552(Pt 2):483-97
pubmed: 14561831
Nature. 2011 Dec 04;481(7379):94-7
pubmed: 22139424
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5562-7
pubmed: 10792058
J Biol Chem. 2008 Aug 29;283(35):24177-84
pubmed: 18559348
FEBS Lett. 2000 May 26;474(1):99-106
pubmed: 10828459
PLoS One. 2015 Dec 16;10(12):e0144800
pubmed: 26672753
J Biol Chem. 2000 Jul 28;275(30):23211-8
pubmed: 10766764
J Neurosci. 2009 Jul 1;29(26):8321-8
pubmed: 19571123
J Neurosci. 1999 Jul 1;19(13):5255-64
pubmed: 10377337
J Magn Reson. 2000 Oct;146(2):249-54
pubmed: 11001840
Biochemistry. 1994 Jan 18;33(2):443-50
pubmed: 7506933
Front Physiol. 2016 Jun 21;7:248
pubmed: 27445840
Biophys J. 2004 May;86(5):2871-82
pubmed: 15111404
J Membr Biol. 2003 Mar 15;192(2):141-8
pubmed: 12682801
Neurosci Bull. 2020 Jan;36(1):11-24
pubmed: 31372899
Proteins. 2003 Aug 1;52(2):146-54
pubmed: 12833539

Auteurs

Xinlian Liu (X)

State Key Laboratory of Bioorganic and Natural Product Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.
University of Chinese Academy of Science, Beijing, China.

Jie Tao (J)

Department of Neurology and Central Laboratory, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Institute of Biomembrane and Biopharmaceutics, Shanghai University, Shanghai, China.

Shuzhang Zhang (S)

Institute of Biomembrane and Biopharmaceutics, Shanghai University, Shanghai, China.

Wenxian Lan (W)

State Key Laboratory of Bioorganic and Natural Product Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.

Yu Yao (Y)

Institute of Biomembrane and Biopharmaceutics, Shanghai University, Shanghai, China.

Chunxi Wang (C)

State Key Laboratory of Bioorganic and Natural Product Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.

Hongjuan Xue (H)

National Facility for Protein Science in Shanghai, Zhangjiang Lab, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China.

Yonghua Ji (Y)

Institute of Biomembrane and Biopharmaceutics, Shanghai University, Shanghai, China.

Guoyi Li (G)

Department of Neurology and Central Laboratory, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Chunyang Cao (C)

State Key Laboratory of Bioorganic and Natural Product Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.
University of Chinese Academy of Science, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Development of charybdotoxin Q18F variant as a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Development of charybdotoxin Q18F variant as a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Development of charybdotoxin Q18F variant as a...
questionsmedicales.fr › Facteurs biologiques › Toxines biologiques › Venins › Venins d'arthropode › Venins de scorpion › Charybdotoxine › Development of charybdotoxin Q18F variant as a...
questionsmedicales.fr › Maladies du système nerveux › Maladies du système nerveux central › Encéphalopathies › Épilepsie › Development of charybdotoxin Q18F variant as a...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Canaux ioniques › Canaux potassiques › Canaux potassiques calcium-dépendants › Canaux potassiques calcium-dépendants de grande conductance › Development of charybdotoxin Q18F variant as a...
questionsmedicales.fr › Cellules › Neurones › Development of charybdotoxin Q18F variant as a...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Development of charybdotoxin Q18F variant as a...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Crises épileptiques › Development of charybdotoxin Q18F variant as a...